HomeCOMMENTARY
COMMENTARY

Pricing Reform Could Goad Drug Makers to Focus Resources on PMP Hopefuls
(Dec.28.2017)

By Yoshinori Sagehashi

Japan’s all-important reimbursement policy panel adopted the government’s drug pricing reform package, with a significant reduction in the scope of eligible on-patent products for the so-called price maintenance premium (PMP). On an off-patent drug front, long-listed products (LLPs), or off-patent brands with generic equivalents, will eventually face phased price cuts based on their generic levels, which will certainly accelerate an increasing move by research-driven makers to offload their LLPs. How exactly will the reform package now affect companies’ new drug development? ...
(LOG IN FOR FULL STORY)